18:30 , May 11, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase Ib data for T cell malignancies candidate

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a single-blind, placebo-controlled, U.S. Phase Ib trial in 25 healthy volunteers showing that multiple ascending doses of T cell malignancies candidate BNZ-1 led to no serious adverse...
16:48 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase I safety data for BNZ-1

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a Phase I trial in 18 healthy volunteers showing that single ascending doses of T cell malignancies candidate BNZ-1 were well tolerated with no serious adverse events...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased efficacy....
07:00 , Aug 1, 2016 |  BC Extra  |  Financial News

Bioniz raises $13M in series A round

Bioniz Therapeutics Inc. (Irvine, Calif.) raised $13 million in a series A round co-led by the Takeda Ventures unit of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and David Pyott, the former chairman and CEO of Allergan...